BR112013024301A2 - uso de peptídeos para detectar, prevenir e curar vitiligo, uso de anticorpo antimia ou fragmento do mesmo e composição para detectar, eviatr e curar vitiligo - Google Patents
uso de peptídeos para detectar, prevenir e curar vitiligo, uso de anticorpo antimia ou fragmento do mesmo e composição para detectar, eviatr e curar vitiligoInfo
- Publication number
- BR112013024301A2 BR112013024301A2 BR112013024301A BR112013024301A BR112013024301A2 BR 112013024301 A2 BR112013024301 A2 BR 112013024301A2 BR 112013024301 A BR112013024301 A BR 112013024301A BR 112013024301 A BR112013024301 A BR 112013024301A BR 112013024301 A2 BR112013024301 A2 BR 112013024301A2
- Authority
- BR
- Brazil
- Prior art keywords
- detect
- vitiligo
- cure
- eviatr
- antimia
- Prior art date
Links
- 206010047642 Vitiligo Diseases 0.000 title 2
- 239000012634 fragment Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/207—Pigmentation disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000134A ITRM20110134A1 (it) | 2011-03-22 | 2011-03-22 | Inibitori di mia (attività inibitoria melanoma) per identificare, prevenire e curare la vitiligine |
PCT/IB2012/051141 WO2012127352A2 (en) | 2011-03-22 | 2012-03-12 | Mia (melanoma inhibitory activity) inhibitors for detecting, preventing and curing vitiligo |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013024301A2 true BR112013024301A2 (pt) | 2018-04-17 |
Family
ID=43977364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013024301A BR112013024301A2 (pt) | 2011-03-22 | 2012-03-12 | uso de peptídeos para detectar, prevenir e curar vitiligo, uso de anticorpo antimia ou fragmento do mesmo e composição para detectar, eviatr e curar vitiligo |
Country Status (15)
Country | Link |
---|---|
US (1) | US20140004130A1 (pt) |
EP (1) | EP2688578B1 (pt) |
JP (1) | JP2014514285A (pt) |
KR (1) | KR20140041466A (pt) |
CN (1) | CN103930122A (pt) |
AU (1) | AU2012232753A1 (pt) |
BR (1) | BR112013024301A2 (pt) |
DK (1) | DK2688578T3 (pt) |
ES (1) | ES2730704T3 (pt) |
IT (1) | ITRM20110134A1 (pt) |
MX (1) | MX2013010891A (pt) |
PL (1) | PL2688578T3 (pt) |
PT (1) | PT2688578T (pt) |
RU (1) | RU2013147195A (pt) |
WO (1) | WO2012127352A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190352335A1 (en) * | 2016-12-19 | 2019-11-21 | Hanmi Pharm. Co., Ltd. | Brain targeting long-acting protein conjugate |
EP3936138A1 (en) * | 2020-07-09 | 2022-01-12 | Bella Aurora Labs, S.A. | Pharmaceutical composition for the treatment of vitiligo |
EP4292581A1 (en) | 2022-06-16 | 2023-12-20 | Bella Aurora Labs, S.A. | Hair repigmenting composition |
EP4385515A1 (en) | 2022-12-16 | 2024-06-19 | Bella Aurora Labs, S.A. | Composition for skin repigmentation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA945278B (en) * | 1993-07-20 | 1996-01-19 | Boehringer Mannheim Gmbh | Melanoma-inhibiting protein |
DE19653358A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Mannheim Gmbh | Immunoassay zum Nachweis von MIA |
NZ520346A (en) * | 2000-03-23 | 2004-07-30 | Akzo Nobel Nv | Use of MIA in immunotherapy |
JP2005528338A (ja) * | 2002-01-29 | 2005-09-22 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 「黒色腫阻害活性物質」(mia)を阻害する方法 |
ES2289544T3 (es) * | 2003-08-12 | 2008-02-01 | Antisense Pharma Gmbh | Oligonucleotido antisentido para inhibir la actividad inhibidora de melanoma mia. |
WO2013033395A1 (en) * | 2011-08-30 | 2013-03-07 | Loyola University Chicago | MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE |
-
2011
- 2011-03-22 IT IT000134A patent/ITRM20110134A1/it unknown
-
2012
- 2012-03-12 EP EP12710120.2A patent/EP2688578B1/en active Active
- 2012-03-12 CN CN201280024894.7A patent/CN103930122A/zh active Pending
- 2012-03-12 JP JP2014500496A patent/JP2014514285A/ja active Pending
- 2012-03-12 WO PCT/IB2012/051141 patent/WO2012127352A2/en active Application Filing
- 2012-03-12 US US14/005,161 patent/US20140004130A1/en not_active Abandoned
- 2012-03-12 PL PL12710120T patent/PL2688578T3/pl unknown
- 2012-03-12 MX MX2013010891A patent/MX2013010891A/es unknown
- 2012-03-12 BR BR112013024301A patent/BR112013024301A2/pt not_active Application Discontinuation
- 2012-03-12 ES ES12710120T patent/ES2730704T3/es active Active
- 2012-03-12 KR KR1020137027850A patent/KR20140041466A/ko not_active Application Discontinuation
- 2012-03-12 RU RU2013147195/15A patent/RU2013147195A/ru not_active Application Discontinuation
- 2012-03-12 DK DK12710120.2T patent/DK2688578T3/da active
- 2012-03-12 AU AU2012232753A patent/AU2012232753A1/en not_active Abandoned
- 2012-03-12 PT PT12710120T patent/PT2688578T/pt unknown
Also Published As
Publication number | Publication date |
---|---|
RU2013147195A (ru) | 2015-04-27 |
CN103930122A (zh) | 2014-07-16 |
PT2688578T (pt) | 2019-05-08 |
ES2730704T3 (es) | 2019-11-12 |
KR20140041466A (ko) | 2014-04-04 |
WO2012127352A2 (en) | 2012-09-27 |
WO2012127352A8 (en) | 2014-03-13 |
JP2014514285A (ja) | 2014-06-19 |
PL2688578T3 (pl) | 2019-07-31 |
US20140004130A1 (en) | 2014-01-02 |
WO2012127352A3 (en) | 2012-12-27 |
MX2013010891A (es) | 2014-03-12 |
ITRM20110134A1 (it) | 2012-09-23 |
EP2688578B1 (en) | 2019-03-27 |
DK2688578T3 (da) | 2019-06-11 |
AU2012232753A1 (en) | 2014-01-23 |
EP2688578A2 (en) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014018136A2 (pt) | anticorpos ou uso e método para determinar | |
BR112013013781A2 (pt) | anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer | |
BR112012022210A2 (pt) | anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado | |
CL2014002750A1 (es) | Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer | |
BR112014032193A2 (pt) | métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico | |
BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
BR112014004168A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção | |
BR112014014547A2 (pt) | compostos antagonistas de e-selectina, composições e métodos de uso | |
BR112013017980A2 (pt) | polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos | |
CO7020870A2 (es) | Anticuerpos anti-htra1 y métodos de uso | |
DK2776469T3 (da) | Antistofmolekyler med specificitet for human ox40 | |
CO6870005A2 (es) | Composición anti-cgrp y uso de las mismas | |
BR112014028366A2 (pt) | anticorpos anti-ly6e e imunoconjugados e métodos de uso | |
BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
CL2015001266A1 (es) | Anticuerpos de antihemaglutinina y métodos de uso. | |
BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
BR112015003938A2 (pt) | métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico | |
BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
BR112014012590A2 (pt) | anticorpos anti-cd98 e métodos de uso dos mesmos | |
BR112013008255A2 (pt) | anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo | |
BR112014009837A2 (pt) | uso eficaz da levedura e extrato de levedura | |
BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
ES2551605T5 (es) | Preparaciones de anticuerpos | |
CO7000747A2 (es) | Anticuerpos anti-lrp5 y métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |